Opinion|Videos|September 10, 2024
HMA Persistence and Effectiveness in Higher Risk MDS
Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Advertisement
Video content above is prompted by the following:
What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and how do these data inform treatment decisions?
- Please include a discussion of 65th American Society of Hematology Annual Meeting and Exposition abstract 548 by Zeidan et al.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
4
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
5